<DOC>
	<DOCNO>NCT00488345</DOCNO>
	<brief_summary>To determine pharmacokinetic profile evaluate safety tolerability ascend multiple dos tigecycline patient age 8 11 year select serious infection ; complicate intra-abdominal infection ( cIAI ) , complicate skin skin structure infection ( cSSSI ) , community-acquired pneumonia ( CAP ) .</brief_summary>
	<brief_title>Study Evaluating Pharmacokinetics ( PK ) , Safety , Tolerability Tigecycline Patients 8 11 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Skin Diseases , Bacterial</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Inclusion Criteria Male female patient age 8 11 year , inclusive , willing able complete activity require study Have diagnosis serious infection ( cIAI , cSSSI CAP ) require hospitalization administration IV antibiotic therapy great equal 5 day Other inclusion criterion apply . Exclusion criteria Patients concomitant condition take concomitant medication , opinion investigator , could preclude evaluation safety efficacy response make unlikely anticipated course therapy followup assessment complete ( e.g. , life expectancy &lt; 30 day ) . Pregnant breastfeed female patient female patient childbearing potential unable unwilling take adequate contraceptive precaution . Previous participation clinical trial . Receipt investigational drug device ( defined lack regulatory agency 's approval within 4 week administration first dose tigecycline ) . Endocarditis ; presence artificial heart valve infect device remove . Known suspected hypersensitivity tigecycline compound related class antibacterial agent ( i.e. , tetracycline ) . Known suspected P. aeruginosa infection . Patients receive immunosuppressive therapy , opinion investigator , would decrease patient 's ability eradicate infection , include use highdose corticosteroid . Receipt organ bone marrow transplant . Presence follow laboratory finding : Neutropenia ( absolute neutrophil count &lt; 1 × 109/L [ &lt; 1000/mm3 ] ) , AST ALT &gt; 10 × ULN bilirubin &gt; 3 × ULN , unless isolate hyperbilirubinemia directly relate acute process ( patient cIAI ) . Patients follow condition : Cystic fibrosis . Active tuberculosis . Congenital immunodeficiency . Meningitis . Septic shock . Osteomyelitis ( suspect evident ) . Refractory shock syndrome hemodynamic parameter maintain despite adequate supportive therapy . Confirmed malignancy patient receive active course chemotherapeutic agent . Known suspect infection human immunodeficiency virus ( HIV ) positive test result HIV antibody . Known suspected concomitant bacterial parasitic infection require systemic treatment . cSSSI patient , presence decubitus ulcer , necrotizing fasciitis , gas gangrene , skeletal infection ; CAP patient hospitalize within 14 day onset symptom ; CAP Patients : Presence follow patient pneumonia : Postobstructive pneumonia . Pulmonary abscess . Empyema . Known suspect pulmonary infection Pneumocystis carinii .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>cIAI</keyword>
	<keyword>cSSSI</keyword>
	<keyword>CAP</keyword>
	<keyword>Child</keyword>
</DOC>